Nxera Pharma Co., Ltd.
JPX: 4565.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher Cargill
- Employees
- 387
- Headquarters
- Tokyo, Japan
- IPO year
- 2004
- Market cap
- ¥105.6B
- Website
- https://soseiheptares.com
Loading 4565…
Loading profile data…Frequently asked questions about 4565
What does Nxera Pharma Co., Ltd. (4565.T) do?
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a n...
Where does 4565.T trade?
Nxera Pharma Co., Ltd. (4565.T) trades on the Tokyo Stock Exchange.
What sector is 4565.T in?
Nxera Pharma Co., Ltd. (4565.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Nxera Pharma Co., Ltd.?
Christopher Cargill is the chief executive officer of Nxera Pharma Co., Ltd. (4565.T).
Where is Nxera Pharma Co., Ltd. headquartered?
Nxera Pharma Co., Ltd. is headquartered in Japan.
Does 4565.T pay a dividend?
Nxera Pharma Co., Ltd. (4565.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4565.T go public?
Nxera Pharma Co., Ltd. (4565.T) completed its initial public offering in 2004.